AERI Aerie Pharmaceuticals Inc.

40.04
+1.34  (+3%)
Previous Close 38.7
Open 38.81
Price To Book 6.78
Market Cap 1819962745
Shares 45,453,615
Volume 1,082,041
Short Ratio
Av. Daily Volume 593,484

NewsSee all news

  1. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
  2. Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019
  3. See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
  4. Mizuho's 9 Best Biotech Stocks to Buy for 2019
  5. Aerie Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?

SEC filingsSee all SEC filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19602902
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595971
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595694
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19590972
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19588055

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date March 14, 2019.
Roclatan
Glaucoma
PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
Rhopressa
Glaucoma

Latest News

  1. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs
  2. Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Monday, February 25, 2019
  3. See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
  4. Mizuho's 9 Best Biotech Stocks to Buy for 2019
  5. Aerie Pharmaceuticals Enters Overbought Territory: Is A Drop Coming?
  6. Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies
  7. A Spotlight On Aerie Pharmaceuticals, Inc.’s (NASDAQ:AERI) Fundamentals
  8. Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-1105 (Dexamethasone Intravitreal Implant)
  9. How to spot risky biotech companies and six to avoid now
  10. Aerie's Rhopressa Succeeds in Study on Japanese Patients
  11. Aerie Pharmaceuticals Announces Positive Topline Results of Netarsudil Ophthalmic Solution in Pilot Phase 2 Study Supporting Clinical Development in Japan
  12. Aerie Pharmaceuticals Announces Appointment of Ami Bavishi as Director, Investor Relations and Vincent Santucci, Pharm.D., as Director, Scientific Market Access
  13. Aerie Division's Prospects Have Analysts Bullish On American Eagle
  14. Hedge Funds Are Selling Aerie Pharmaceuticals Inc (AERI)
  15. Should You Get Rid of Aerie Pharmaceuticals (AERI) Now?
  16. Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar — Discovering Underlying Factors of Influence

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19602902
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595971
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595694
  4. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19590972
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19588055
  6. 8-K - Current report 19587544
  7. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19582051
  8. SC 13G - Statement of acquisition of beneficial ownership by individuals 19563679
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19563660
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19562051